Lexeo director granted options for 35,000 shares
Lexeo Therapeutics director Steven Altschuler received a grant of options covering 35,000 shares of Common Stock.
Rhea-AI Filing Summary
Lexeo Therapeutics director Steven Altschuler received a grant of options covering 35,000 shares of Common Stock. The stock options have an exercise price of $4.70 per share and expire on June 24, 2036. All 35,000 underlying shares vest and become exercisable on the earlier of one year after the grant date or the next annual meeting of stockholders, as long as he remains in continuous service. Following this award, he holds 35,000 stock options directly, and the transaction reflects a compensation-related grant rather than an open-market purchase.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 35,000 shares
Grant/Award
1 txn
Insider
Altschuler Steven
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 35,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (right to buy) — 35,000 contracts (Direct)
Footnotes (1)
- F1. 100% of the shares underlying the option shall vest, and become exercisable, on the earlier of one year following the grant date or the next annual meeting of stockholders, subject to the Reporting Person's continuous service on such date.
Key Figures
Option grant size: 35,000 shares
Exercise price: $4.70 per share
Expiration date: June 24, 2036
+1 more
4 metrics
Option grant size
35,000 shares
Stock Option (right to buy) awarded to director
Exercise price
$4.70 per share
Conversion or exercise price of granted options
Expiration date
June 24, 2036
Option term end date
Post-transaction derivative holdings
35,000 options
Total shares following transaction for this option grant
Key Terms
Stock Option (right to buy), grant/award acquisition, Common Stock, exercise price, +2 more
6 terms
Stock Option (right to buy) financial
"security_title: Stock Option (right to buy)"
grant/award acquisition financial
"transaction_action: grant/award acquisition"
Common Stock financial
"underlying_security_title: Common Stock"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
exercise price financial
"conversion_or_exercise_price: 4.7000"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: 2036-06-24T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
continuous service financial
"subject to the Reporting Person's continuous service on such date"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Lexeo Therapeutics (LXEO) director Steven Altschuler report on this Form 4?
Steven Altschuler reported receiving a stock option grant for 35,000 shares of Lexeo Therapeutics Common Stock. The options were awarded as compensation, not bought on the open market, and give him the right to purchase shares at a fixed exercise price in the future.
What is the exercise price and expiration date of Steven Altschuler’s Lexeo Therapeutics options?
The stock options have an exercise price of $4.70 per share and an expiration date of June 24, 2036. This means he can choose to buy shares at $4.70 any time after vesting and before the June 2036 expiration, if he elects to exercise.
When do Steven Altschuler’s Lexeo Therapeutics stock options vest?
All 35,000 option shares vest on the earlier of one year after the grant date or the next annual meeting of stockholders. Vesting is conditioned on his continuous service with Lexeo Therapeutics through that date, according to the Form 4 footnote disclosure.
Is Steven Altschuler buying or selling Lexeo Therapeutics (LXEO) stock in this Form 4?
He is not buying or selling shares on the market in this filing. The Form 4 reports a compensation-related grant of stock options, giving him the right to purchase shares later, rather than an immediate open-market transaction in Lexeo Therapeutics stock.
How many Lexeo Therapeutics derivative securities does Steven Altschuler hold after this transaction?
After the reported grant, he holds 35,000 stock options directly, as shown by the total shares following the transaction. These represent rights to acquire Common Stock in the future, subject to vesting and the June 24, 2036 expiration date specified in the Form 4.
AI-generated analysis. How Rhea-AI works. Not financial advice.
